Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Guida

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
ESMO Open|August 28, 2020
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre studyAnastasia Constantinidou, Nicolas Sauve, Silvia Stacchiotti, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 3, 2012
The cost of unresectable stage III or stage IV melanoma in ItalyMichele Maio, Paolo Ascierto, Alessandro Testori, et al.
Journal of Translational Medicine|September 12, 2024
An artificial intelligence-based model exploiting H&E images to predict recurrence in negative sentinel lymph-node melanoma patientsMaria Colomba Comes, Livia Fucci, Sabino Strippoli, et al.
Cells|June 28, 2023
The Impact of O6-Methylguanine-DNA Methyltransferase (<i>MGMT</i>) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with DacarbazineLucia Cannella, Rosa Della Monica, Antonella Lucia Marretta, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2006
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South ItalyMilena Casula, Maria Colombino, Maria P Satta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain MetastasesAnna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2024
Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531]Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
Journal of Neuro-Oncology|February 18, 2014
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Francesco Spagnolo, Paolo Antonio Ascierto, et al.
Targeted Oncology|November 10, 2021
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
ESMO Open|August 28, 2020
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre studyAnastasia Constantinidou, Nicolas Sauve, Silvia Stacchiotti, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 3, 2012
The cost of unresectable stage III or stage IV melanoma in ItalyMichele Maio, Paolo Ascierto, Alessandro Testori, et al.
Journal of Translational Medicine|September 12, 2024
An artificial intelligence-based model exploiting H&E images to predict recurrence in negative sentinel lymph-node melanoma patientsMaria Colomba Comes, Livia Fucci, Sabino Strippoli, et al.
Cells|June 28, 2023
The Impact of O6-Methylguanine-DNA Methyltransferase (<i>MGMT</i>) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with DacarbazineLucia Cannella, Rosa Della Monica, Antonella Lucia Marretta, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2006
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South ItalyMilena Casula, Maria Colombino, Maria P Satta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain MetastasesAnna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2024
Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531]Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, et al.
Journal of Neuro-Oncology|February 18, 2014
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Francesco Spagnolo, Paolo Antonio Ascierto, et al.
Targeted Oncology|November 10, 2021
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, et al.
Pageof 13